南微医学科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688029 证券简称：南微医学 南微医学科技股份有限公司 2024 年年度股东大会会议资料 2025 年 5 月 | 议案 | 年度薪酬及 7《关于确认公司董事、监事 2024 2025 年度薪酬方案的议案》...15 | | --- | --- | | 听取《公司 | 2024 年度独立董事述职报告》： | | | | 南微医学科技股份有限公司 2024 年年度股东大会会议资料 南微医学科技股份有限公司 2024 年年度股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大 会的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华 人民共和国证券法》《上市公司股东会规则》以及《南微医学科技股份有限公司章 程》（以下简称"《公司章程》"）《南微医学科技股份有限公司股东大会议事规则》 等相关规定，南微医学科技股份有限公司（以下简称"公司"）特制定本次股东大会 会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作人 员将对出席会议者的身份进行必要的核对工作，请被核对者 ...

Group 1 - The company announced a share repurchase plan with a total expected amount between 30 million to 50 million RMB [1][2] - The repurchase will be conducted through centralized bidding and is set to last for 6 months after board approval [1][2] - The maximum repurchase price is capped at 150% of the average trading price over the last 30 trading days, which is 96.54 RMB per share [1] Group 2 - As of the latest update, the company has repurchased a total of 15,729 shares, representing 0.0084% of the total share capital of 187,847,422 shares [2] - The repurchase was executed at a price range between 62.01 RMB and 62.32 RMB per share, with a total expenditure of approximately 977,391.79 RMB [2] - The company will adhere to relevant regulations and will disclose further information regarding the repurchase progress [2]

| 回购方案首次披露日 | 2025/4/22，由董事长隆晓辉先生提议 | | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 6 个月 | | 预计回购金额 | 3,000万元~5,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 15,729股 | | 累计已回购股数占总股本比例 | 0.0084% | | 累计已回购金额 | 977,391.79元 | | 实际回购价格区间 | 62.01元/股~62.32元/股 | 证券代码：688029 证券简称：南微医学 公告编号：2025-023 南微医学科技股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、回购股份的基本情况 2025 年 4 月 21 日，南微医学科技股份有限公司（以下简称"公司"）召开第 四届董事会第八次会议，审议通过了《关于以集中竞价交 ...

Investment Rating - The report maintains an "Outperform" rating for the company [4][9]. Core Insights - In 2024, the company achieved revenue of 2.76 billion RMB, representing a year-on-year growth of 14.26%, and a net profit attributable to shareholders of 553 million RMB, up 13.85% [4][9]. - The company is experiencing steady domestic revenue growth despite temporary pressure from centralized procurement, with domestic sales reaching 1.38 billion RMB in 2024, a 2.1% increase year-on-year [4][9]. - Export revenue is growing rapidly, with 2024 export revenue at 1.36 billion RMB, a 30.44% increase year-on-year, contributing nearly 40% of total profits [4][9]. - The company has forecasted EPS for 2025-2027 at 3.55, 4.24, and 5.02 RMB respectively, with a target price of 88.75 RMB based on a 2025 target PE of 25X [4][9]. Financial Summary - The company’s financial performance shows a steady increase in revenue and profit margins, with a gross profit margin of 67.65% in 2024, up 3.15 percentage points from the previous year [4][9]. - The net profit margin for 2024 was 20.62%, reflecting a slight increase of 0.10 percentage points [4][9]. - The company’s sales expense ratio decreased to 23.46%, while the management expense ratio was 19.71% [4][9]. - The company’s total assets are projected to grow from 4.39 billion RMB in 2023 to 5.99 billion RMB by 2027 [6].

Group 1 - The company plans to repurchase shares with a total amount not less than RMB 30 million and not exceeding RMB 50 million [10][24] - The source of funds for the repurchase will be the company's own funds or a special loan from CITIC Bank Nanjing Branch [10][24] - The repurchased shares will be used for employee stock ownership plans or equity incentives [14][21] Group 2 - The repurchase price will not exceed RMB 96.54 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [23][24] - The repurchase will be conducted through centralized bidding on the Shanghai Stock Exchange [16][21] - The repurchase period is set for six months from the date the board approves the plan [11][17] Group 3 - The company aims to enhance investor confidence and improve shareholder returns through this repurchase [14][31] - The total number of shares to be repurchased is estimated to be between 310,753 shares (0.17% of total shares) and 517,920 shares (0.28% of total shares) based on the maximum repurchase amount [21][22] - The board of directors has confirmed that there are no plans for share reductions by major shareholders in the next three to six months [29][30] Group 4 - The board of directors approved the repurchase proposal on April 21, 2025, with unanimous support [13][31] - The company has established a dedicated securities account for the repurchase of shares [36] - The company will disclose the progress of the repurchase plan in a timely manner [36][8]

证券代码：688029 证券简称：南微医学 公告编号：2025-022 南微医学科技股份有限公司 关于以集中竞价方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份方式：集中竞价交易方式； ● 回购股份期限：自公司董事会审议通过本次回购方案之日起 6 个月内； ● 相关股东是否存在减持计划：经公司发函确认，截至董事会通过本次回购方案 决议之日，除公司第一大股东回复在未来 3 个月暂无减持所持公司股份的计划， 未来 6 个月是否减持暂不确定外，其他持股 5%以上的股东、回购提议人、其他董 事、监事、高级管理人员均回复其在未来 3 个月、未来 6 个月不存在减持公司股 份的计划。若上述人员或股东未来拟实施股份减持计划，公司将按相关规定及时 履行信息披露义务。 ● 相关风险提示： ● 回购股份金额：不低于人民币 3,000.00 万元（含），不超过人民币 5,000.00 万元（含）； ● 回购股份资金来源：公司自有资金或中信银行股份有限公司南京分行（以下简 称"中信银行南京分行 ...

关于召开2024年度暨 2025年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 投资者可于2025年5月8日(星期四)至5月12日(星期一)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或将有关问题通过电子邮件 的形式发送至公司投资者关系邮箱nwyx@mtmed.com。公司将在说明会上对 投资者普遍关注的问题进行回答。 证券代码：688029 证券简称：南微医学 公告编号：2025-021 南微医学科技股份有限公司 董事、总裁冷德嵘先生，董事、执行总裁李常青先生，高级副总裁兼财务 负责人芮晨为先生，独立董事吴应宇先生，副总裁兼董事会秘书龚星亮先生 （如有特殊情况，参会人员可能进行调整）。 四、 投资者参加方式 一、 说明会类型 南微医学科技股份有限公司（以下简称"公司"）已于2025年4月29日在上 海证券交易所网站（www.sse.com.cn）披露《2024年年度报告》和《2025年第 一季 ...

证券研究报告 南微医学 (688029 CH) 24 年海外亮眼，1Q25 业绩稳定增长 | 华泰研究 | | | 年报点评 | | --- | --- | --- | --- | | 2025 年 | 4 月 | 29 日│中国内地 | 医疗器械 | 公司 2024 年收入/归母净利润/扣非归母净利润 27.55/5.53/5.44 亿元，同比 +14.3%/+13.9%/+17.5% ； 1Q25 收 入 / 归母净利润 / 扣 非 归 母 净 利 润 6.99/1.61/1.61 亿元，同比+12.8%/+12.2%/+14.2%。24 年业绩符合业绩快 报，1Q25 收入及归母净利润稳定增长。我们看好后续集采影响消化后业绩 增长提速，维持买入评级。 24 年国内收入同比稳健增长，海外收入快速增长 1）国内：24 年受国内集采影响，GI 产品线增长受阻，国内收入 13.82 亿 元，同比+2.1%，整体保持稳健，但受益于产品成本降低，国内毛利率达 68.7%，同比+3.2pct；2）海外：24 年海外市场业绩表现亮眼，公司通过美 国、欧洲、日本等多家海外子公司，构建全球化稳定营销体系，海外收入 13.5 ...

Group 1: Fixed Income Market - The recent volatility in the US Treasury market is largely attributed to the upcoming June maturity, which may be overestimated in terms of its impact on financial markets [2] - In the short term, the supply pressure from maturing US Treasuries is expected to be limited, with a more significant focus on the debt ceiling adjustments anticipated in Q3 [2] - Long-term demand for US Treasuries may face a downward trend, with potential alternatives including European and Japanese bonds, as well as gold [2] Group 2: Technology Sector - The report discusses India's potential as the next manufacturing hub for Apple, highlighting the competitive tariff advantages for Indian exports compared to China [4] - Apple theoretically has the capacity to produce the required number of iPhones in India, but initial production will still rely on Chinese exports due to current limitations [4] - The localization of components in India is still in its early stages, with significant reliance on supply chains from other Asian countries for critical parts [4] Group 3: Energy and New Energy - The lithium battery production forecast for May shows a slight decline in overall production, primarily due to the cancellation of mandatory storage policies and the impact of US tariffs on exports [5] - Despite short-term fluctuations, the long-term outlook for the lithium battery industry remains positive, driven by new vehicle models and technologies [5] - Recent power outages in Spain, Portugal, and southern France have underscored the need for investment in grid upgrades and DC grid technology, presenting opportunities for Chinese power equipment companies [6] Group 4: Media and Publishing - Phoenix Media reported a Q1 2025 revenue of 3.226 billion yuan, reflecting a year-over-year decline, but a significant increase in net profit due to continued tax incentives [7] - The company maintains a stable core business and is rated as a "buy" based on its solid performance and favorable tax policies [7] Group 5: Financial Sector - The report indicates that the China Construction Bank's Q1 2025 net profit and revenue showed slight year-over-year changes, with a focus on asset quality and credit expansion [9] - The bank's diversified income sources and stable operations support a "buy" rating [9] Group 6: Consumer Goods - The report highlights the strong performance of China National Offshore Oil Corporation, with Q1 revenues showing a significant year-over-year increase, driven by stable oil and gas production [20] - The company is expected to maintain a "buy" rating due to its robust operational performance and project advancements [20] Group 7: Real Estate - The report notes that China Petroleum's Q1 2025 revenue and net profit exceeded expectations, attributed to increased natural gas production and sales [34] - The company is rated as "increase" based on its strong performance and potential for further growth in the natural gas sector [34]

正式报名：首届全球心血管大会 | 赠送纸质白皮书 合作伙伴征集：2025全球手术机器人大会 2025年4月28日， 南微医学 发布2024年年报及2025年一季报。 # 财务数据 公司2024年实现收入 27.55亿 元（同比 +14.26% ）， 归母净利润5.53亿元（同比+13.85%），扣非归母 净利润5.44亿元（同比+17.48%）。 据此计算， 2024Q4单季度实现收入 7.43亿 元（同比 +11.54% ） ，归母净利润1.02亿元（同比 +2.75%），扣非归母净利润0.98亿元（同比+14.67%）。 公司2025年一季度实现收入 6.99亿 元（同比 +12.75% ）， 归母净利润1.61亿元（同比+12.18%），扣非 归母净利润1.61亿元（同比+14.20%）。 # 关于 南微医学 南微医学科技股份有限公司是一家主要从事 分产品： 内镜耗材类收入23.28亿元（同比+13.50%）；肿瘤介入类收入2.18亿元（同比 +19.14%）；可视化类收入0.36亿元（同比-46.21%）；其他类收入1.60亿元（同比+67.41%）。 分地区： 内销收入13.82亿元（同比+2.10 ...